126 related articles for article (PubMed ID: 37844418)
1. Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.
Low HC; Tay YS; Ong SYK; Tham WY; Yan SX
Clin Nucl Med; 2023 Dec; 48(12):1086-1088. PubMed ID: 37844418
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
3. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [
Siebinga H; Hendrikx JJMA; de Vries-Huizing DMV; Huitema ADR; de Wit-van der Veen BJ
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):820-827. PubMed ID: 37843598
[TBL] [Abstract][Full Text] [Related]
4.
Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
[TBL] [Abstract][Full Text] [Related]
5. Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.
Somoza EA; Duan H; Shaheen S; Fischer GA; Aparici CM
Clin Nucl Med; 2022 Nov; 47(11):961-962. PubMed ID: 35695695
[TBL] [Abstract][Full Text] [Related]
6. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
7. Long-Acting Somatostatin Analog Therapy Differentially Alters
Ayati N; Lee ST; Zakavi R; Pathmaraj K; Al-Qatawna L; Poon A; Scott AM
J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
[TBL] [Abstract][Full Text] [Related]
8. 177 Lu-DOTATATE PRRT for Multiple Unusual Metastatic Sites in Neuroendocrine Tumor.
Parghane RV; Basu S
Clin Nucl Med; 2022 Oct; 47(10):874-875. PubMed ID: 35353741
[TBL] [Abstract][Full Text] [Related]
9. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
10. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
[TBL] [Abstract][Full Text] [Related]
11. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
13. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
14. Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
Pirisino R; Filippi L; D'Agostini A; Bagni O
Clin Nucl Med; 2022 Nov; 47(11):e692-e695. PubMed ID: 35695716
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
18. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
[TBL] [Abstract][Full Text] [Related]
19. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
